El-Sisi, Alaa E <br/><br/>
Targeting MDR-1 gene expression, BAX/BCL2, caspase-3, and Ki-67 by nanoencapsulated imatinib and hesperidin to enhance anticancer activity and ameliorate cardiotoxicity.  [electronic resource] 

 -  Fundamental & clinical pharmacology  Aug 2020 
 - 458-475 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1472-8206 
<br/><br/><label>Standard No.: </label>10.1111/fcp.12549  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ATP Binding Cassette Transporter, Subfamily B, Member 1--genetics<br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--chemistry<br/>Breast Neoplasms--drug therapy<br/>Carcinoma, Ehrlich Tumor--drug therapy<br/>Cardiotoxicity<br/>Caspase 3--metabolism<br/>Drug Carriers<br/>Drug Compounding<br/>Female<br/>Heart Diseases--chemically induced<br/>Humans<br/>Imatinib Mesylate--chemistry<br/>Indoles--chemistry<br/>Ki-67 Antigen--metabolism<br/>MCF-7 Cells<br/>Mice<br/>Nanoparticles<br/>Polylactic Acid-Polyglycolic Acid Copolymer--chemistry<br/>Proto-Oncogene Proteins c-bcl-2--metabolism<br/>Signal Transduction<br/>Sulfonamides--chemistry<br/>Tumor Burden--drug effects<br/>bcl-2-Associated X Protein--metabolism